Jazz Pharmaceuticals (NASDAQ:JAZZ) CAO Sells $326,911.68 in Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CAO Patricia Carr sold 1,413 shares of the business’s stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $231.36, for a total transaction of $326,911.68. Following the completion of the sale, the chief accounting officer owned 6,512 shares of the company’s stock, valued at approximately $1,506,616.32. This represents a 17.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $234.76 on Monday. The company has a 50 day moving average price of $229.39 and a 200-day moving average price of $217.74. Jazz Pharmaceuticals PLC has a fifty-two week low of $128.80 and a fifty-two week high of $266.38. The stock has a market capitalization of $15.07 billion, a PE ratio of 79.85, a PEG ratio of 0.43 and a beta of 0.38. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.64 and a current ratio of 1.82.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.03) by $0.15. The firm had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.21 billion. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. The company’s quarterly revenue was up 10.4% on a year-over-year basis. During the same period last year, the firm earned $8.13 earnings per share. Equities analysts predict that Jazz Pharmaceuticals PLC will post 11.08 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of large investors have recently made changes to their positions in JAZZ. Castleark Management LLC acquired a new stake in Jazz Pharmaceuticals during the 1st quarter worth about $9,214,000. SEB Asset Management AB purchased a new position in shares of Jazz Pharmaceuticals during the 1st quarter valued at about $8,765,000. Bank of America Corp DE lifted its holdings in shares of Jazz Pharmaceuticals by 10.9% in the 1st quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock valued at $191,848,000 after buying an additional 99,656 shares during the period. California Public Employees Retirement System lifted its holdings in shares of Jazz Pharmaceuticals by 10.6% in the 1st quarter. California Public Employees Retirement System now owns 124,583 shares of the specialty pharmaceutical company’s stock valued at $23,552,000 after buying an additional 11,915 shares during the period. Finally, Angeles Wealth Management LLC acquired a new position in shares of Jazz Pharmaceuticals in the 2nd quarter valued at about $1,221,000. 89.14% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz beat quarterly estimates, reporting $1.24 billion in revenue versus roughly $1.21 billion expected, with revenue up 10.4% year over year. Coverage also reported that the company raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, helping reinforce the growth outlook. Q3 results and outlook
• Positive Sentiment: RBC, Barclays, Morgan Stanley and JPMorgan issued favorable commentary or raised price targets after the results. The analyst optimism adds support to the stock’s post-earnings momentum. Barclays price-target update
• Neutral Sentiment: CEO Renée Galá sold 1,000 shares under a pre-arranged Rule 10b5-1 plan and retained 140,394 shares. Director Bruce Cozadd also sold 6,000 shares under a pre-arranged plan, while CAO Patricia Carr sold 1,413 shares and retained 6,512. These sales may draw investor attention, but planned transactions are not necessarily a signal about near-term business prospects. Insider transaction coverage

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Deutsche Bank Aktiengesellschaft upped their price objective on Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a “buy” rating in a research note on Wednesday, August 26th. Barclays lifted their target price on Jazz Pharmaceuticals from $271.00 to $275.00 and gave the company an “overweight” rating in a research note on Tuesday, November 3rd. The Goldman Sachs Group started coverage on shares of Jazz Pharmaceuticals in a report on Thursday, September 24th. They issued a “buy” rating and a $337.00 target price for the company. JPMorgan Chase & Co. increased their price target on shares of Jazz Pharmaceuticals from $300.00 to $310.00 and gave the company an “overweight” rating in a research report on Tuesday, November 3rd. Finally, UBS Group raised their price target on shares of Jazz Pharmaceuticals from $315.00 to $337.00 and gave the company a “buy” rating in a report on Friday, September 11th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $293.45.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets.

Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.

Jazz expanded its portfolio through acquisitions, including the 2021 acquisition of GW Pharmaceuticals, which added Epidiolex and other cannabinoid-based medicines.